St. Jude Reference #SJ-02-0016
Human vaccines, including those for influenza, are traditionally grown in embryonated chicken eggs. Advances in influenza reverse genetics lead to the possibility of using cell culture systems to produce influenza vaccines; however, the replicative complex used in current vaccines does not grow well in this system. Researchers at St. Jude developed a modification of the genetic makeup of the influenza virus backbone that results in a replicative complex that does grow well in cell culture, particularly in Vero cell culture. Influenza vaccine strains made with this modified viral backbone have increased yield and speed of growth in cell culture, which are very desirable traits in vaccine production. Application of this invention helps to make the transfer of traditional vaccine production from eggs to cell culture systems feasible.
Human influenza virus, vaccine production, Vero cells, reverses genetics
Granted Patents or Published Applications
US Patent No. 7,037,707
Related Scientific References
Ozaki H, et al. Generation of high-yielding Influenza A viruses in African green monkey kidney (Vero) cells by reverse genetics. J of Virol 78(4):1851-1857, February 2004;
Hoffmann E, et al. DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci, 97(11):6108-6013, May 23, 2000;
Neumann G, et al. Generation of influenza A viruses entirely from cloned cDNAs. Proc Natl Acad Sci, 96(16):9345-9350, Aug. 3, 1999;
Govorkova E, et al. Growth and immunogenicity of influenza viruses cultivated in Vero or MDCK cells and in embryonated chicken eggs. Dev Biol Stan 98:39-51, discussion 73-74;
Govorkova E, African green monkey kidney (Vero) cells provide an alternative host cell system for influenza A and B viruses. J Virol 70(8):5519-5524, Aug 1996;
Govorkova E, et al. Replication of influenza A viruses in a green monkey kidney continuous cell line (Vero). J Infect Dis 172(1):250-253, July 1995.
We are currently seeking licensing opportunities in all fields for the development of this technology. Contact: email@example.com
Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.